The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden
Open accessAbstract
// Adam E. Frampton 1, 2, * , Mireia Mato Prado 2, * , Elena López-Jiménez 2 , Ana Belen Fajardo-Puerta 1 , Zaynab A.R. Jawad 1 , Phillip Lawton 2 , Elisa Giovannetti 3, 4 , Nagy A. Habib 1 , Leandro Castellano 2, 5 , Justin Stebbing 2, # , Jonathan Krell 2, # and Long R. Jiao 1, # 1 HPB Surgical Unit, Department of Surgery and Cancer, Imperial College, London, UK 2 Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK 3 Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands 4 Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy 5 University of Sussex, School of Life Sciences, John Maynard Smith Building, Falmer, Brighton, UK * These authors share co-first authorship # These authors share co-senior authorship Correspondence to: Long R. Jiao, email: l.jiao@imperial.ac.uk Keywords: Glypican-1 (GPC1); pancreatic ductal adenocarcinoma (PDAC); exosome; biomarker; tumor size Received: October 28, 2017 Accepted: March 02, 2018 Published: April 10, 2018 ABSTRACT Background: Glypican-1 (GPC1) is expressed in pancreatic ductal adenocarcinoma (PDAC) cells and adjacent stromal fibroblasts. Recently, GPC1 circulating exosomes (crExos) have been shown to be able to detect early stages of PDAC. In this study, we investigated the usefulness of crExos GPC1 as a biomarker for PDAC. Methods: Plasma was obtained from patients with benign pancreatic disease ( n = 16) and PDAC ( n = 27) prior to pancreatectomy, and crExos were isolated by ultra-centrifugation. Protein was extracted from surgical specimens (adjacent normal pancreas, n = 13; and PDAC, n = 17). GPC1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Results: There was no significant difference in GPC1 levels between normal pancreas and PDAC tissues. This was also true when comparing matched pairs. However, GPC1 levels were enriched in PDAC crExos ( n = 11), compared to the source tumors ( n = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; P < 0.001). In addition, PDACs with high GPC1 expression tended to have crExos with higher GPC1 levels. Despite these findings, we were unable to distinguish PDAC from benign pancreatic disease using crExos GPC1 levels. Interestingly, we found that in matched pre and post-operative plasma samples there was a significant drop in crExos GPC1 levels after surgical resection for PDAC ( n = 11 vs. 11; 97 ± 54 vs. 77.8 ± 32.4 pg/mL; P = 0.0428). Furthermore, we found that patients with high crExos GPC1 levels have significantly larger PDACs (>4 cm; P = 0.012). Conclusions: High GPC1 crExos may be able to determine PDAC tumor size and disease burden. However, further efforts are needed to elucidate its role as a diagnostic and/or prognostic biomarker using larger cohorts of PDAC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., LeBleu, V. S., Mittendorf, E. A., Weitz, J., Rahbari, N., et al. (2015) · Nature · doi:10.1038/nature14581 · Cited by 2,880
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
Exosomes in cancer: Use them or target them?
Bastos, N., Ruivo, C. F., da Silva, S., & Melo, S. A. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.08.009 · Cited by 140
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
The evolving translational potential of small extracellular vesicles in cancer
Möller, A., & Lobb, R. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00299-w · Cited by 544
Single-Exosome-Counting Immunoassays for Cancer Diagnostics
Liu, C., Xu, X., Li, B., Situ, B., Pan, W., Hu, Y., An, T., Yao, S., & Zheng, L. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01184 · Cited by 406
Gurunathan, S., Kang, M.-H., & Kim, J.-H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s291956 · Cited by 379
Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics
Karamanos, N. K., Piperigkou, Z., Theocharis, A. D., Watanabe, H., Franchi, M., Baud, S., Brézillon, S., Götte, M., Passi, A., Vigetti, D., et al. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00354 · Cited by 367
Metadata
- Authors
- Frampton, A. E., Prado, M. M., López-Jiménez, E., Fajardo-Puerta, A. B., Jawad, Z. A. R., Lawton, P., Giovannetti, E., Habib, N. A., Castellano, L., Stebbing, J., Krell, J., & Jiao, L. R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-10
- Volume
- 9
- Issue
- 27
- Pages
- 19006-19013
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2797486656
- Cited by
- 160
- References
- 5
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.